DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication
Artículo científico (JournalArticle)
Apolipoprotein and lrp1‐based peptides as new therapeutic tools in atherosclerosis
Apolipoprotein (Apo)‐based mimetic peptides have been shown to reduce atherosclerosis. Most of the ApoC‐II and ApoE mimetics exert anti‐atherosclerotic effects by improving lipid profile. ApoC‐II mimetics reverse hypertriglyceridemia and ApoE‐based peptides such as Ac‐hE18A‐NH2 reduce cholesterol and triglyceride (TG) levels in humans. Conversely, other classes of ApoE and ApoA‐I mimetic peptides and, more recently, ApoJ and LRP1‐based peptides, exhibit several antiatherosclerotic actions in experimental models without influencing lipoprotein profile. These other mimetic peptides display at least one atheroprotective mechanism such as providing LDL stability against mechanical modification or conferring protection against the action of lipolytic enzymes inducing LDL aggregation in the arterial intima. Other anti‐atherosclerotic effects exerted by these peptides also include protection against foam cell formation and inflammation, and induction of reverse cholesterol transport. Although the underlying mechanisms of action are still poorly described, the recent findings suggest that these mimetics could confer atheroprotection by favorably influencing lipoprotein function rather than lipoprotein levels. Despite the promising results obtained with peptide mimetics, the assessment of their stability, atheroprotective efficacy and tissue targeted delivery are issues currently under progress., The economic support was received from Fundació MARATÓ TV3 with the grant 201521-
10 (to V.L.C), FIS PI18/01584 (to V.L.C) and FIS PI19/00421 (to S.B.) from the Instituto de Salud
Carlos III (ISCIII) and co-financed with ERDFs and from Ayudas Fundación BBVA a Equipos de
Investigación Científica en Biomedicina 2019. A.B.A. is a predoctoral fellow (FI19/00205) granted by
the Programme _Contratos predoctorales de formación de investigación en salud_and J.J. is recipient
of a Miguel Servet Type 2 contract (CPII18/00004) from the Instituto de Salud Carlos III (ISCIII)
and co-financed with ERDFs. E.G. Grant support was also received from Fundación BBVA (Project
“Translational Molecular Imaging for Detection of Cholesterol Entrapment in the Vasculature with
68Ga-labeled LRP1-derived Peptides”). The team is part of CIBER Enfermedades Cardiovasculares
(CIBERCV; CB16/11/00276 to V.L.C.) and CIBER Diabetes y Enfermedades Metabólicas Asociadas
(CIBERDEM; CB07/08/0016 to J.J.), projects run by the Instituto de Salud Carlos III. The team also
participates in Redes de investigación (Enfermedades Metabólomicas y Cáncer RED2018-102799-T), a
project run by MINECO. A.B.A., E.G., J.J., S.B. and V.L.C. are members of the Vascular Biology Group
of the Spanish Atherosclerosis Society.
Project:
MINECO RED2018-102799-T
View at: http://hdl.handle.net/10261/260059